» Articles » PMID: 11773079

Functional Interaction of STAT3 Transcription Factor with the Coactivator NcoA/SRC1a

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Jan 5
PMID 11773079
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Signal transducer and activator of transcription 3 (STAT3) transcription factors are cytoplasmic proteins that induce gene activation in response to cytokine receptor stimulation. Following tyrosine phosphorylation, STAT3 proteins dimerize, translocate to the nucleus, and activate specific target genes. This transcriptional activation by STAT3 proteins has been shown to require the recruitment of coactivators such as CREB-binding protein (CBP)/p300. In the present study, we show that steroid receptor coactivator 1, NcoA/SRC1a, originally identified as a nuclear receptor coactivator, also functions as a coactivator of STAT3 proteins. In coimmunoprecipitations, NcoA/SRC1a was found to associate with STAT3 following IL-6 stimulation of HepG2 hepatoma cells. Pull-down experiments indicated that the N-terminal part of NcoA/SRC1a associates with the activation domain of STAT3. Overexpression of NcoA/SRC1a or its SRC1e isoform enhanced transcriptional activation by STAT3 proteins in transient transfection experiments. This ability of NcoA/SRC1a to enhance STAT3 activity is dependent upon the presence of the CBP-interacting domain, activation domain 1. Using chromatin immunoprecipitation assays, we found that STAT3, NcoA/SRC1a, and CBP/p300 are simultaneously recruited to the p21(waf1) promoter following interleukin-6 stimulation. Taken together, these data suggest that CBP/p300 and NcoA/SRC1a may function in a common pathway to regulate STAT3 transcriptional activity.

Citing Articles

HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules.

Khatkar P, Mensah G, Ning S, Cowen M, Kim Y, Williams A Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256867 PMC: 10819208. DOI: 10.3390/ph17010033.


STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Groschke S Mol Cancer. 2023; 22(1):133.

PMID: 37573301 PMC: 10422794. DOI: 10.1186/s12943-023-01825-8.


STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo.

Rohrer K, Song H, Akbar A, Chen Y, Pramanik S, Wilder P Cancers (Basel). 2023; 15(8).

PMID: 37190167 PMC: 10136921. DOI: 10.3390/cancers15082239.


Screening of potent STAT3-SH2 domain inhibitors from JAK/STAT compound library through molecular dynamics simulation.

Manoharan S, Balakrishnan A, Hemamalini V, Perumal E Mol Divers. 2022; 27(3):1297-1308.

PMID: 35831728 DOI: 10.1007/s11030-022-10490-w.


Nuclear Receptor Coregulators in Hormone-Dependent Cancers.

Jafari H, Hussain S, Campbell M Cancers (Basel). 2022; 14(10).

PMID: 35626007 PMC: 9139824. DOI: 10.3390/cancers14102402.